Muhammad Nadjad bin Abdul Rahim

Dr Nadjad is exploring ways to translate discoveries in the lab to actual products used in clinics. This involves the development of medical devices in an ISO-13485 compliant manner to reduce risks in translating the research into full-fledged medical devices. On the horizon, Dr Nadjad is exploring new methods in the rapidly advancing field of sequencing from the chemistry of kits to bioinformatics which can be applied to a wide field of clinical applications from cancer to infectious diseases. Dr Nadjad also leads the development of affordable, highly sensitive and multiplexed detection of viruses for use in wastewater-based epidemiology. Dr Nadjad is also actively working on machine learning and bioinformatics methods and developing datasets suitable for future medicine.

ISO-13485 compliant Diagnostics Reagents Development.

DNA/RNA Sequencing.

dPCR/PCR Methods Development.

Bioinformatics.

Molecular Biology.

Cancer, Infectious Disease, Immune Disease Molecular Diagnostics Development.

Dr Nadjad completed his Ph.D. in the National University of Singapore under the supervision of Prof Jackie Ying. He joined the A*STAR spin-off Cellbae Pte Ltd first as a Research Director winning a competitive Singapore Food Agency (SFA) Agriculture Productivity Fund R&D Grant ($691,263) as PI looking at multiplexed detection of poultry production diseases. Then, as Product Development and Operations Director, he led the design to validation and manufacturing of molecular PCR kits covering the whole suite of activities from research to market. He also led a successful clinical trial validation for lateral flow assay. Cellbae also provided molecular testing services for the surveillance of aquatic animals in the whole of Singapore. He led the team in the first identification of Tilapia Lake Virus (TiLV) in Singapore following an episode of significant fishkill affecting farms. Dr Nadjad has been awarded the Public Service Medal by the Republic of Singapore.